Sample ID | Age (years) | Sex | Bacterial isolation | Antibiotherapy before blood collection | Underlying diseases | Survival |
---|---|---|---|---|---|---|
Other sepsis (n = 11) | Â | Â | Â | Â | Â | Â |
   I016* †| 61 | Female | Coagulase-negative staphylococci | Ceftazidime, bactrim, Sulperazole | Hematemesis | Survivor |
   I017* ‡§ | 50 | Male | Coagulase-negative staphylococci | Ceftriaxone, ceftazidime, doxycycline, cloxacillin | Acute pancreatitis, nephrotic syndrome | Survivor |
   I018§¶¥ | 57 | Male | Coagulase-negative staphylococci# | Vancomycin | T2D, CRF | Survivor |
   I019¤ | 58 | Female | Staphylococcus aureus | Cloxacillin, ceftazidime | T2D, wound | Survivor |
   I020¶¥ | 66 | Female | Coagulase-negative staphylococci# | Ceftazidime, ceftriaxone | T2D, ARF, tuberculosis | Non-survivor |
   I021¶ | 54 | Female | Enterococcus spp. | Ceftazidime, cloxacilin | T2D, abscess | Non-survivor |
   I022§¶ | 37 | Male | Coagulase-negative staphylococci# | Ceftriaxone, ceftazidime | T2D, ARF | Non-survivor |
   I023¶¤ | 70 | Female | E. coli | Doxycycline, ceftazidime | T2D | Non-survivor |
   I024¶¥ | 56 | Male | Coagulase-negative staphylococci | Meropenem, ceftazidime | T2D, RF | Survivor |
   I025* | 50 | Male | S. pneumoniae | Ceftriaxone, meropenem | T2D | Non-survivor |
   I026¶ | 57 | Male | K. pneumoniae | Ceftriaxone, ceftazidime, bactrim | T2D | Survivor |
Septicemic melioidosis (n = 13) | Â | Â | Â | Â | Â | Â |
   M016¶ | 39 | Male | B. pseudomallei | Ceftazidime, bactrim, doxycycline | T2D | Survivor |
   M017¶ | 52 | Female | B. pseudomallei | Norfloxacin, ceftazolin | T2D | Survivor |
   M020¶ | 61 | Male | B. pseudomallei | Ceftriaxone, doxycycline, ceftazidime | - | Survivor |
   M021¶ | 56 | Female | B. pseudomallei | Ceftriaxone, ceftazidime | T2D | Survivor |
   M022¶ | 18 | Male | B. pseudomallei | Ceftazidime, cactrim | T2D | Survivor |
   M023¶ | 63 | Male | B. pseudomallei | Bactrim, ceftazidime | T2D | Survivor |
   M024¶ | 44 | Male | B. pseudomallei | Meropenem | T2D, RF | Survivor |
   M025¶ | 57 | Male | B. pseudomallei | Ceftazidime | T2D | Survivor |
   M026¶ | 48 | Male | B. pseudomallei | Ceftazidime, doxycycline, bactrim | T2D | Survivor |
   M027¶ | 44 | Male | B. pseudomallei | Ceftriaxone, ceftazidime, meropenem | ARF | Survivor |
   M028¶ | 70 | Male | B. pseudomallei | Ceftazidime, levofloxacin, bactrim | T2D | Survivor |
   M029¶ | 50 | Male | B. pseudomallei | Ceftriaxone, ceftazidime | CRF | Non-survivor |
   M030¶ | 44 | Male | B. pseudomallei | Ceftazidime, ceftriazone | T2D, tuberculosis | Survivor |